BioCentury | Jul 13, 2018
Finance

Pause for politics

...NASDAQ:UBX) 5/2/18 $85.0 $712.4 $641.1 -10% Surface Oncology Inc. (NASDAQ:SURF) 4/18/18 $108.0 $414.0 $446.8 8% Medigen Vaccine Biologics Corp....
BioCentury | Jan 13, 2018
Finance

Choosy investors

...Ltd. 8/29/17 Up to 86.3M Ph II Axium Pharmaceuticals Inc. 8/21/17 Up to $5M Preclin Medigen Vaccine Biologics Corp....
BioCentury | Oct 6, 2017
Finance

High as a Kite

...TissueGene Inc. (KOSDAQ) 8/31/17 KRW32.3B ($29M) Mkt (drug) Sol-Gel Technologies Ltd. 8/29/17 $86.3M Ph II Medigen Vaccine Biologics Corp....
BioCentury | Aug 3, 2015
Financial News

Medigen Vaccine financial update

...Medigen Vaccine Biologics Corp. , Taipei, Taiwan Business: Infectious Date announced: 2015-07-29 Note: Medigen Vaccine Biologics began...
BioCentury | Mar 27, 2000
Tools & Techniques

MediGene's validation play with Schering

MediGene AG was to announce today that it has formed a worldwide alliance to develop its Viral Vaccine with Schering AG for the treatment of precancerous cervica MediGene (Munich, Germany) is using protein fusion technology...
BioCentury | Feb 16, 2000
Company News

MediGene and Aventis cancer deal

Aventis (AVE; NM:AVE; DAX:AVE) received an exclusive license to develop and commercialize MediGene's vaccine to treat malignant melanoma in 37 countries, including the European Union, U.S., Japan and Canada. MediGene (Martinsried, Germany) could receive up...
Items per page:
1 - 6 of 6
BioCentury | Jul 13, 2018
Finance

Pause for politics

...NASDAQ:UBX) 5/2/18 $85.0 $712.4 $641.1 -10% Surface Oncology Inc. (NASDAQ:SURF) 4/18/18 $108.0 $414.0 $446.8 8% Medigen Vaccine Biologics Corp....
BioCentury | Jan 13, 2018
Finance

Choosy investors

...Ltd. 8/29/17 Up to 86.3M Ph II Axium Pharmaceuticals Inc. 8/21/17 Up to $5M Preclin Medigen Vaccine Biologics Corp....
BioCentury | Oct 6, 2017
Finance

High as a Kite

...TissueGene Inc. (KOSDAQ) 8/31/17 KRW32.3B ($29M) Mkt (drug) Sol-Gel Technologies Ltd. 8/29/17 $86.3M Ph II Medigen Vaccine Biologics Corp....
BioCentury | Aug 3, 2015
Financial News

Medigen Vaccine financial update

...Medigen Vaccine Biologics Corp. , Taipei, Taiwan Business: Infectious Date announced: 2015-07-29 Note: Medigen Vaccine Biologics began...
BioCentury | Mar 27, 2000
Tools & Techniques

MediGene's validation play with Schering

MediGene AG was to announce today that it has formed a worldwide alliance to develop its Viral Vaccine with Schering AG for the treatment of precancerous cervica MediGene (Munich, Germany) is using protein fusion technology...
BioCentury | Feb 16, 2000
Company News

MediGene and Aventis cancer deal

Aventis (AVE; NM:AVE; DAX:AVE) received an exclusive license to develop and commercialize MediGene's vaccine to treat malignant melanoma in 37 countries, including the European Union, U.S., Japan and Canada. MediGene (Martinsried, Germany) could receive up...
Items per page:
1 - 6 of 6